LQDA Stock Forecast & Price Target

Liquidia is supported by a differentiated PRINT platform that can precisely engineer uniform particles and fit a faster, more capital-efficient 505(b)(2) pathway, which gives the company a structurally attractive way to develop improved versions of established APIs. Its commercial momentum is strong, with Yutrepia’s 2Q26 revenue of $170.4M, 31% quarter-over-quarter growth, about 5,000 patients started on treatment, nearly 5,900 unique prescriptions written, more than 1,100 prescribers, and cash and equivalents of $284.2M, while management also guided to more than $1B in 2027 net revenue. The outlook is further reinforced by broadening payer coverage, expanding sales efforts into an underpenetrated community setting, a growing inhaled prostacyclin market, and a pipeline of 10 clinical studies plus L606 and other programs that could extend the franchise and protect it against competitive and dosing-related limitations.

Liquidia is positioned around a potentially large but still underpenetrated pulmonary hypertension market, yet the investment case remains fundamentally tied to a single asset, Yutrepia, and therefore carries meaningful concentration risk if adoption, execution, or the legal backdrop disappoints. While the company has shown improving operating momentum with 2Q26 net income of $74.7MM, adjusted EBITDA of $96.3MM, and cash rising by $61.4MM quarter over quarter to roughly $284MM, the negative outlook reflects that profitability is still highly dependent on commercialization success in PAH and PH-ILD and on whether Yutrepia can truly defend a durable competitive position. The pending patent litigation with United Therapeutics remains the most important overhang, because even though the judge’s active engagement is procedurally encouraging, the dispute still injects uncertainty into the core thesis, and the longer-term pipeline outside Yutrepia is described as underappreciated rather than de-risked.